- Home
- GNTA vs MIST Comparison
GNTA vs MIST Comparison
Compare GNTA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | MIST |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Italy | Canada |
| Employees | 13 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 176.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNTA | MIST |
|---|---|---|
| Price | $0.72 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 51.3K | ★ 1.7M |
| Earning Date | 03-24-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.63 |
| 52 Week High | $10.00 | $3.06 |
Technical Indicators
Market Signals| Indicator | GNTA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 24.45 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.70 | $2.01 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 38.36 | 0.00 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).